Immunomodulatory drugs.
After nearly decades of extinction as a sedative and antiemetic, thalidomide reemerged as the parent compound of a novel and promising class of therapeutics termed the immunomodulatory drugs (IMiDs). The analogues of thalidomide, CC-5013 (lenalidomide, Revlimid) and CC-4047 (Actimid) are more potent regulators of cellular immune and cytokine response while lacking some of the dose limiting side effects of the parent compound, such as neurologic toxicity. Preclinical data will be reviewed that outlines these drugs' effects on tumor necrosis alpha, interleukin 12, angiogenesis, and T-cell function. The evolution of the use of thalidomide as a therapeutic for diseases such as multiple myeloma and myelodysplastic syndrome and the promising initial results of the new IMiDs will be reviewed.
Crane
Edward
E
Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, and University of South Florida College of Medicine, Tampa 33612, USA.
List
Alan
A
D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D018664:Interleukin-12 / Q000502:physiology; D000077269:Lenalidomide; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D009389:Neovascularization, Pathologic; D013601:T-Lymphocytes / Q000187:drug effects / Q000502:physiology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D018664:Interleukin-12; D013792:Thalidomide; C467566:pomalidomide; D000077269:Lenalidomide